Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Exicure, Inc. (XCUR : NSDQ)
 
 • Company Description   
Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.

Number of Employees: 47

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.12 Daily Weekly Monthly
20 Day Moving Average: 11,776,648 shares
Shares Outstanding: 122.81 (millions)
Market Capitalization: $14.86 (millions)
Beta: 1.60
52 Week High: $1.98
52 Week Low: $0.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -29.81% -20.95%
12 Week -27.46% -20.24%
Year To Date -40.13% -26.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2430 N. Halsted St.
-
Chicago,IL 60614
USA
ph: 847-673-1700
fax: -
ksharma@macbiocom.com http://www.exicuretx.com
 
 • General Corporate Information   
Officers
Matthias Schroff - Chief Executive Officer; President and Director
Elizabeth Garofalo - Chair of the Board of Directors
Elias D. Papadimas - Chief Financial Officer
Jeffrey L. Cleland - Director
Bali Muralidhar - Director

Peer Information
Exicure, Inc. (CORR.)
Exicure, Inc. (RSPI)
Exicure, Inc. (CGXP)
Exicure, Inc. (BGEN)
Exicure, Inc. (GTBP)
Exicure, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 30205M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 122.81
Most Recent Split Date: (:1)
Beta: 1.60
Market Capitalization: $14.86 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.59
Price/Cash Flow: -
Price / Sales: 4.06
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 53.33%
Sales Growth
vs. Year Ago Period: 157.27%
vs. Previous Quarter: 21.10%
ROE
03/31/22 - -368.55
12/31/21 - -229.15
09/30/21 - -155.30
ROA
03/31/22 - -92.58
12/31/21 - -84.02
09/30/21 - -73.91
Current Ratio
03/31/22 - 1.37
12/31/21 - 1.28
09/30/21 - 2.92
Quick Ratio
03/31/22 - -
12/31/21 - 1.28
09/30/21 - 2.92
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -5,527.46
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.03
12/31/21 - 0.10
09/30/21 - 0.16
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 1.20
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 54.58
 

Powered by Zacks Investment Research ©